BioSpace News Archive

Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that a manuscript on the variability of contraceptive clinical trial design and its impact on efficacy outcomes has been published in the peer-reviewed journal Advances in Therapy.

Vaxart, Inc. (NASDAQ: VXRT), today announced the appointment of James F. Cummings, M.D., as the Company’s Chief Medical Officer (CMO). Dr. Cummings is a Board-Certified Infectious Diseases Physician with extensive experience in vaccine, drug and diagnostics development.

Syros Pharmaceuticals today announced the appointment of Conley Chee as the company’s first Chief Commercial Officer.

Cyclo Therapeutics Appoints Lise Lund Kjems, MD, PhD as Chief Medical Officer

AnHeart Therapeutics Co., Ltd together with Innovent Biologics, Inc. announced today interim clinical data from a Phase Ⅱ trial (TRUST) evaluating taletrectinib (AB-106)

EQRx today announced the appointment of Kathy Giusti to the Company’s board of directors.

ChemoCentryx, Inc., announced that Kissei Pharmaceutical Co., Ltd. has received approval from the Japanese Ministry of Health, Labor, and Welfare to market TAVNEOS™ in Japan for the treatment of patients with microscopic polyangiitis and granulomatosis with polyangiitis, the two main forms of anti-neutrophil cytoplasmic autoantibody-associated vasculitis also known as ANCA-associated vasculitis or ANCA vasculitis.

Precision BioSciences, Inc. today announced that Michael Amoroso has been named as the Company’s President and Chief Executive Officer and a member of the Precision BioSciences Board of Directors, in each case effective October 15, 2021.

Aviceda is partnering with world-renowned glyco-chemist Prof. Geert-Jan Boons and analytical glyco-biologist Dr. Parastoo Azadi and their teams at Complex Carbohydrate Research Center (CCRC) to spearhead development of the next generation of glyco-immune therapeutics

Intra-Cellular Therapies, Inc. today announced the publication of the results from its lumateperone monotherapy Phase 3 clinical trial (ITI-007-404).